ArticleThe Journal of steroid biochemistry and molecular biology2010
Tumor progression in the LPB-Tag transgenic model of prostate cancer is altered by vitamin D receptor and serum testosterone status.
Article in The Journal of steroid biochemistry and molecular biology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 48 citations in OpenAlex.
- Vitamin D Receptor in Cancer: Biological Functions, Mechanistic Insights, and Clinical Relevance.Cancer management and research · 2026Review
- Diverse landscape of genetically engineered mouse models: Genomic and molecular insights into prostate cancer.Cancer letters · 2024Review
- Non-Musculoskeletal Benefits of Vitamin D beyond the Musculoskeletal System.International journal of molecular sciences · 2021Review
- Molecular Basis of Prostate Cancer and Natural Products as Potential Chemotherapeutic and Chemopreventive Agents.Frontiers in pharmacology · 2021Review
- Review
- Skeletal and Extraskeletal Actions of Vitamin D: Current Evidence and Outstanding Questions.Endocrine reviews · 2019Review
- Review
- Vitamin D Signaling Suppresses Early Prostate Carcinogenesis in TgAPTCancer prevention research (Philadelphia, Pa.) · 2019Article
- Do dietary calcium and vitamin D matter in men with prostate cancer?Nature reviews. Urology · 2018Review
- Vitamin D, PCOS and androgens in men: a systematic review.Endocrine connections · 2018Review
- Extraskeletal actions of vitamin D.Annals of the New York Academy of Sciences · 2016Review
- Vitamin D and cancer: the promise not yet fulfilled.Endocrine · 2014Review
- Vitamin D, intermediary metabolism and prostate cancer tumor progression.Frontiers in physiology · 2014Review
- Molecular link between vitamin D and cancer prevention.Nutrients · 2013Review
- Role of androgen and vitamin D receptors in endothelial cells from benign and malignant human prostate.American journal of physiology. Endocrinology and metabolism · 2013Review
- Cellular and molecular effects of vitamin D on carcinogenesis.Archives of biochemistry and biophysics · 2012Review
- Vitamin D and cancer: a review of molecular mechanisms.The Biochemical journal · 2012Review
- 1,25-Dihydroxyvitamin D(3) regulates PTHrP expression via transcriptional, post-transcriptional and post-translational pathways.Molecular and cellular endocrinology · 2011Article
- Effects of 1α,25 dihydroxyvitamin D3 and testosterone on miRNA and mRNA expression in LNCaP cells.Molecular cancer · 2011Article
- Vitamin d, sunlight and prostate cancer risk.Advances in preventive medicine · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
Previous studies have suggested that 1,25 dihydroxyvitamin D(3) (1,25(OH)2D3) induces cell cycle arrest and/or apoptosis in prostate cancer cells in vitro, suggesting that vitamin D may be a useful adjuvant therapy for prostate cancer and a chemopreventive agent. Most epidemiological data however shows a weak link between serum 25(OH)D3 and risk of prostate cancer. To explore this dichotomy we have compared tumor progression in the LPB-Tag model of prostate in VDR knock out (VDRKO) and wild type (VDRWT) mice. On the C57BL/6 background LPB-Tag tumors progress significantly more rapidly in the VDRKO mice. VDRKO tumors show significantly higher levels of cell proliferation than VDRWT tumors. In mice supplemented with testosterone to restore the serum levels to the normal range, these differences in tumor progression, and proliferation are abrogated, suggesting that there is considerable cross-talk between the androgen receptor (AR) and the vitamin D axis which is reflected in significant changes in steady state mRNA levels of the AR, PCNA, cdk2 survivin and IGFR1 and 2 genes. These alterations may explain the differences between the in vitro data and the epidemiological studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.